echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Lilly LOXO announced that it will work with Melus to develop three CD3 dual anti-drugs

    Lilly LOXO announced that it will work with Melus to develop three CD3 dual anti-drugs

    • Last Update: 2021-01-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On January 20, Lilly's LOXO announced that it would work with Melus to develop three CD3 dual anti-drugs.
    Lilly will pay a down payment of 40 million down payments and 20 million shares, each product can get up to 540 million miles, the total value of the cooperation can reach 1.6 billion, if the product available melu can also get about 10% sales.
    Melus's technology platform, called ®, claims to have found more than 170 light chains of CD3 antibodies of different properties.
    believes cd3 dual resistance is becoming the most disruptive cancer immunotherapy.
    mecus today took advantage of a 6 percent rise in its stock to announce it would raise $60 million.
    recently terminated the clinical development of two dual-anti-products, PD-L1/TIM-3 dual-resistant LY3321367 and an IL-23/CGRP dual-anti.
    is currently at the forefront of hot antibody drugs, but truly successful drugs are rare.
    U.S. has listed only CD3/CD19 dual anti-Blincyto and F8 factor simulator Hemlibra, but johnson-Johnson's cMET/EFFR dual-resistance performance has also been good recently.
    the current clinical stage of the dual resistance to CD3 dual resistance-based, design concepts and CAR-T, ADC similar are the killing mechanism and tumor-specific antigens through the combination of dual resistance.
    , however, there are still significant barriers to dual-anti-production and medicinality, LY3321367 is said to have been abandoned because of immunogenicity, and Hemlibra has been found to have neutralized antibody production since its launch.
    limited specific antigens for solid tumor tumors also limit this technique.
    not much of a double resistance outside of tumours, although Hemlibra, which accounts for half of the population, is a haemophilia drug.
    CD3 double resistance has attracted a lot of resources since the launch of Blincyto and the more similar CAR-T therapy, Lilly seems to be coming in a little late.
    this is the norm in the pharmaceutical ecosystem, and big drugmakers often wait until technology is relatively mature.
    almost all new technologies are in this order, biotech companies venture into new areas, and big drug companies come in to buy and commercialize, such as the recent layout of big drugs in gene therapy and gene editing.
    one is that such a cutting-edge platform takes a long time to explore to find its full value, and the other is that small biotech companies are struggling to compete with these Big Macs in the marketplace.
    Many people say that big drug companies lack the spirit of innovation, biotechnology companies are the source of new drug innovation, in fact, there are big drug companies more bloated factors, but there are also vulnerable biotechnology companies forced to stay in high-risk areas of the factors.
    to the executive power-based late clinical development, approval, marketing and other activities are the strengths of large pharmaceutical technology, if the implementation path is clear these old big drug factory combat effectiveness can not be ignored.
    dual-functional drugs are a major area of drug design because many diseases are not caused by a protein failure.
    sometimes regulates a protein that controls disease but requires a high dose of the drug, and the introduction of a second regulatory mechanism can significantly reduce the effective dose.
    traditional multi-target drug design is a fusion of two drugs, one bird and two stone, such as Lilly's own GIP/GLP double agitant tirzepatide, which recently produced stunning data in late-stage clinical trials.
    drugs with poor early selection, such as most central nervous drugs, also regulate a variety of targets, but belong to the screening of multi-target drugs, have the taste of eating by the sky.
    the current dual-functional drug design more rational and precise, space-based design ideas of technology has become a major direction.
    addition to dual resistance and a variety of techniques to induce protein degradation, protein degradation mechanisms such as E3 linked enzymes are brought closer in space to therapeutic targets.
    drug-induced polymerization is also a frontier.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.